- Home
- TERN vs AURA Comparison
TERN vs AURA Comparison
Compare TERN & AURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TERN
- AURA
- Stock Information
- Founded
- TERN 2017
- AURA 2007
- Country
- TERN United States
- AURA United States
- Employees
- TERN N/A
- AURA N/A
- Industry
- TERN Biotechnology: Pharmaceutical Preparations
- AURA Biotechnology: Pharmaceutical Preparations
- Sector
- TERN Health Care
- AURA Health Care
- Exchange
- TERN Nasdaq
- AURA Nasdaq
- Market Cap
- TERN 586.0M
- AURA 572.0M
- IPO Year
- TERN 2021
- AURA 2021
- Fundamental
- Price
- TERN $6.17
- AURA $9.47
- Analyst Decision
- TERN Buy
- AURA Strong Buy
- Analyst Count
- TERN 6
- AURA 4
- Target Price
- TERN $16.42
- AURA $23.00
- AVG Volume (30 Days)
- TERN 1.3M
- AURA 184.2K
- Earning Date
- TERN 11-12-2024
- AURA 11-12-2024
- Dividend Yield
- TERN N/A
- AURA N/A
- EPS Growth
- TERN N/A
- AURA N/A
- EPS
- TERN N/A
- AURA N/A
- Revenue
- TERN N/A
- AURA N/A
- Revenue This Year
- TERN N/A
- AURA N/A
- Revenue Next Year
- TERN N/A
- AURA N/A
- P/E Ratio
- TERN N/A
- AURA N/A
- Revenue Growth
- TERN N/A
- AURA N/A
- 52 Week Low
- TERN $3.59
- AURA $6.63
- 52 Week High
- TERN $11.40
- AURA $12.38
- Technical
- Relative Strength Index (RSI)
- TERN 31.82
- AURA 39.43
- Support Level
- TERN $6.99
- AURA $10.48
- Resistance Level
- TERN $7.53
- AURA $11.29
- Average True Range (ATR)
- TERN 0.47
- AURA 0.56
- MACD
- TERN -0.02
- AURA -0.18
- Stochastic Oscillator
- TERN 16.57
- AURA 2.67
About TERN Terns Pharmaceuticals Inc.
Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, NASH, and other chronic liver diseases.
About AURA Aura Biosciences Inc.
Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its lead candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.